Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)—rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients

Abstract Kidney transplant recipients are at an increased risk of severe COVID-19-associated hospitalisation and death. Vaccination has been a key public health strategy to reduce disease severity and infectivity, but the effectiveness of COVID vaccines is markedly reduced in kidney transplant recip...

Full description

Bibliographic Details

Published in:	Trials
Main Authors:	Matthew Tunbridge, Griffith B. Perkins, Julian Singer, Tania Salehi, Tracey Ying, Branka Grubor-Bauk, Simon Barry, Beatrice Sim, Pravin Hissaria, Steven J. Chadban, P. Toby Coates
Format:	Article
Language:	English
Published:	BMC 2022-09-01
Subjects:	Kidney transplantation Randomised controlled trial Sirolimus Immunosuppression SARS-CoV-2 COVID-19
Online Access:	https://doi.org/10.1186/s13063-022-06634-w